Jieran Long

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

SMARCA4-deficient thoracic tumors exhibit an immunosuppressive microenvironment and respond to combined antiangiogenic and immune checkpoint inhibitor therapy.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 04, 2025

Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort Study.

Treatment Efficacy, Chemoradiotherapy Benefits, and Survival Disparities by Histology in Primary Mediastinal Germ Cell Tumors: 15-Year Results of a Single-Center Cohort Study.

Journal: Asia-Pacific journal of clinical oncology

Published: April 01, 2025

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China.

Journal: Frontiers in oncology

Published: February 16, 2025

Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.

Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.

Journal: BMC cancer

Published: December 16, 2024

Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study.

Need Analysis of Clinician-Oriented Integrated Precision Oncology Decision Support Tools: Qualitative Descriptive Study.

Journal: JMIR human factors

Published: October 14, 2024

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Phase Ib/II study on the safety, tolerability, and preliminary efficacy of pegylated irinotecan (JK1201I) as second-line monotherapy for patients with small-cell lung cancer.

Journal: Cancer medicine

Published: March 17, 2024

Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.

Nivolumab combined docetaxel versus nivolumab in patients with previously treated nonsmall cell lung cancer: a phase 2 study.

Journal: Anti-cancer drugs

Published: January 19, 2024

Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.

Real-world data on the first-line immune checkpoint inhibitors or in combination with chemotherapy in older patients (aged ≥ 75 years) with advanced non-small cell lung cancer.

Journal: Heliyon

Published: September 21, 2023

Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis.

Construction of an endoplasmic reticulum stress-related signature in lung adenocarcinoma by comprehensive bioinformatics analysis.

Journal: BMC pulmonary medicine

Published: August 31, 2022

The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies.

The overall survival benefit in Chinese ALK+ NSCLC patients received targeted therapies.

Journal: Journal of thoracic disease

Published: March 31, 2022

Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.

Second-line treatment options in advanced thymic carcinoma after failure of platinum-based chemotherapy: A multicenter retrospective study.

Journal: Cancer medicine

Published: December 19, 2021

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.

Pembrolizumab or Bevacizumab Plus Chemotherapy as First-Line Treatment of Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Retrospective Cohort Study.

Journal: Technology in cancer research & treatment

Published: November 25, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026